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Myelin-specificCD8+T cells are thought to contribute
to the pathogenesis of multiple sclerosis. Here we
modeled this contribution in mice with CD8+ T cells
recognizing ovalbumin (OVA) expressed in oligoden-
drocytes (ODCs). Surprisingly, even very high
numbers of activated OVA-reactive CD8+ T cells
failed to induce disease and were cleared from the
immune system after antigen encounter in the
central nervous system (CNS). Peripheral infection
with OVA-expressing Listeria (Lm-OVA) enabled
CD8+ T cells to enter the CNS, leading to the deletion
of OVA-specific clones after OVA recognition on
ODCs. In contrast, intracerebral infection allowed
OVA-reactive CD8+ T cells to cause demyelinating
disease. Thus, in response to infection, CD8+ T cells
also patrol the CNS. If the CNS itself is infected,
they destroyODCs upon cognate antigen recognition
in pursuit of pathogen eradication. In the sterile brain,
however, antigen recognition onODCs results in their
deletion, thereby maintaining tolerance.
INTRODUCTION
Multiple sclerosis (MS) is an autoimmune disease characterized
by accumulation of lymphocytes andmacrophages in the central
nervous system (CNS), with localized inflammation and demye-
lination of axons. Depending on the subtype of MS, multiple
immune cells are detected in the lesions, including CD4+ and
CD8+ T cells (Bru¨ck et al., 2002). A pathogenic role of the latter
is supported by several observations: acute and chronic lesions
of MS patients contain more CD8+ than CD4+ T cells (Crawford
et al., 2004; Tsuchida et al., 1994), expanded myelin-reactive
cytotoxic T lymphocyte (CTL) clones are found in the CNS and
the periphery of MS patients (Babbe et al., 2000), and depletion
of CD4+ T cells in MS patients fails to improve relapse rates
whereas global T cell depletion leads to their reduction (Coles
et al., 1999; Hohlfeld and Wiendl, 2001).
In the CNS, antigen recognition by CD8+ T cells is hampered
by low expression of major histocompatibility complex (MHC)
class I antigens on neurons, oligodendrocytes (ODCs), and134 Immunity 37, 134–146, July 27, 2012 ª2012 Elsevier Inc.astrocytes, suggesting microglia and resident dendritic cells
(DCs) as prime targets for antigen recognition by CD8+ T cells.
However, MHC I expression is upregulated by inflammation,
and ODC-derived myelin antigens have indeed been identified
as targets for autoreactive CD8+ T cells in both humans
(Jurewicz et al., 1998) and mice (Saxena et al., 2008). Accord-
ingly, the clonal CD8+ T cell expansions in MS are likely to reflect
myelin-specific autoimmunity.
In experimental autoimmune encephalomyelitis (EAE), a group
of animal models for MS, disease is classically induced by
peripheral immunization with myelin antigens in proinflammatory
adjuvants or by transfer of encephalitogenic CD4+ T cells (Gold
et al., 2006). In recent years, however, it has been attempted
to also recapitulate the CD8+ T cell component of the disease
in several mouse models: MHC class I-restricted T cell receptor
(TCR)-transgenic mice with specificity for myelin autoantigens
have been developed (Friese et al., 2008; Huseby et al., 2001;
Ji et al., 2010), and model antigens to which well-characterized
TCR-transgenic mouse lines are available have been expressed
in the CNS (Na et al., 2008; Saxena et al., 2008). In adoptive
transfer experiments analogous to those previously performed
with encephalitogenic CD4+ T cells, however, it has been
extremely difficult to induce clinically apparent disease. For
example, transfer of very high numbers (3 3 107, corresponding
to about 10% of the endogenous CD8+ T cell population) of
in vitro preactivated hemagglutinin (HA)-specific CTLs induces
EAE in less than half of recipients expressing HA in ODCs
(Saxena et al., 2008). In another model employing TCR-trans-
genic myelin basic protein (MBP)-specific CTLs, disease induc-
tion requires transfer of 2 3 107 preactivated cells, conditioning
by irradiation, and treatment with interleukin-2 (IL-2) (Huseby
et al., 2001). In contrast, as few as 106 and 105 MBP-specific
cloned CD4+ T cells suffice to induce EAE in rats (Ben-Nun
et al., 1981) and mice (Zamvil et al., 1985), respectively, indi-
cating that the pathogenic potency of activated autoreactive
CD4+ T cells exceeds that of their CTL counterparts by more
than two orders of magnitude.
As a second option to providing overwhelming numbers of
autoreactive CD8+ T cells, TCR transgenic mouse lines have
been generated in which all or most CD8+ T cells are specific
for a natural or artificial myelin antigen. Depending on central
tolerance induction and a requirement for peripheral priming,
disease is observed in some (Friese et al., 2008; Ji et al., 2010;
Na et al., 2008) but not in other (Perchellet et al., 2004; Saxena
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a role for CD8+ T cells in human MS, experimental induction of
disease with autoreactive CD8+ T cells in mice requires a CD8+
T cell assault of amagnitude that can hardly be consideredwithin
the range of physiology.
In our own studies, we have generatedmice that express oval-
bumin (OVA) under the proximal MBP promoter (ODC-OVAmice)
leading to sequestration of this model antigen in the cytosol of
ODCs (Cao et al., 2006). When crossed to OT-I mice expressing
a transgenic TCR recognizing the OVA-derived SIINFEKL
peptide presented by H-2Kb, ODC-OVA mice spontaneously
develop lethal EAE at 2 weeks of age; in contrast, OVA-specific
TCR-transgenic CD4+ T cells developing in ODC-OVA mice
remain ignorant of the sequestered autoantigen (Cao et al.,
2006; Na et al., 2008).
To study the effect of peripheral induction of ODC-specific
autoimmunity in mice with a normal T cell repertoire, we have
now infected ODC-OVA mice with OVA-expressing Listeria
monocytogenes (Lm-OVA), which elicits a strong CD8+ T cell
response to the SIINFEKL peptide. Unexpectedly, we observed
resistance to EAE induction that wasmediated by clonal deletion
of autoreactive CD8+ T cells from the entire immune system. In
contrast, infection of the CNS itself rendered the OVA-express-
ing ODCs susceptible to destruction by OVA-specific CTLs, indi-
cating that the decision between effective immune surveillance
versus tolerance induction is made by the perception of infection
in the brain itself.
RESULTS
Lack of OVA-Specific CD8+ T Cell Response
in Lm-OVA-Infected ODC-OVA Mice
To induce a CD8+ T cell-mediated autoimmune response against
ODCs by peripheral immunization, ODC-OVA mice, in which
ODCs express cytosolic OVA, were infected with Lm-OVA.
However, EAE symptoms, T cell infiltration, or inflammation of
the CNS were not observed either during primary or during
secondary infection (data not shown).
In WT mice, Lm-OVA infection elicits massive expansion of
SIINFEKL-specific CD8+ T cells, which can make up more than
30% of the CD8+ T cell compartment at the peak of the response
(Figure 1A; Pope et al., 2001). This response was almost
completely absent in Lm-OVA-infected ODC-OVA mice, indi-
cating that a deletional mechanism acting either during T cell
development or during the immune response itself protected
the mice from autoimmune attack (Figure 1A).
ODC-OVA Mice Lack OVA-Kb-Reactive CD8+ T Cells
ToclarifywhetherOVA-reactiveCD8+ T cellsweredeleted before
or after Lm-OVA infection, 23 108 WT or ODC-OVA lymph node
(LN) cells were transferred into Rag1/ mice, which were then
infected with Lm-OVA. Mice that had received LN cells from
ODC-OVA donors showed hardly any OVA-specific CD8+ T cell
response, whereas mice reconstituted with WT cells responded
well (Figure 1B), indicating that OVA-reactive CD8+ T cells were
deleted in ODC-OVA mice already before Lm-OVA infection.
To confirm this without the need to induce a response to OVA,
we crossed ODC-OVA mice with ‘‘Vb5 mice’’ that express only
the b chain of the OT-I TCR and therefore have a detectable pop-ulation of Kb-OVA-reactive CD8+ T cells generated by pairing of
polyclonal TCRa chains with the transgenic b chain (Dillon et al.,
1994). Vb5 ODC-OVA mice remained healthy and without CNS
infiltrates (not shown). When their CD8+ T cell repertoire was
compared to that of Vb5 single transgenic mice, we observed
only a small difference in the frequency of Kb-OVA-reactive
CD8+ T cells by using Kb-OVA-multimer staining, which detects
high- and low-avidity cells (Figure 1C). However, comparison of
the functional avidity of Kb-OVA-reactive CD8+ T cells from
single and double transgenic mice revealed that high-avidity
OVA-reactive T cells had been completely deleted in ODC-
OVA mice (Figure 1D).
Deletion of OVA-Reactive CD8+ T Cells Is Not Mediated
by Thymic or Peripheral Stroma Cells or by
Hematopoietic Cells
Because purging of autoreactive CD8+ T cells from the T cell
repertoire can be mediated by radioresistant cells both during
thymic maturation and in the periphery, we tested whether
OVA-specific CD8+ T cells developing in irradiated ODC-OVA
mice would also be deleted. Adult mice, in which T cells are
excluded from the CNS in the absence of immune activation,
were chosen as recipients. Bone marrow cells from WT and
OT-I Thy1.1 mice were transplanted at a 4:1 ratio into irradiated
WT or ODC-OVA mice, and T cell reconstitution from both
inocula was analyzed 6 weeks later. Representation of mature
OT-I cells in the CD8+ T cell repertoire was identical in WT and
ODC-OVA recipients (Figure 1E), and their response (prolifera-
tion and interferon-g [IFN-g] secretion) to the SIINFEKL peptide
was unaffected by the host (WT or ODC-OVA) in which they
had matured (Figure 1F). In keeping with our previous biochem-
ical results (Na et al., 2008), this indicates that the neo-self
antigen OVA is expressed neither in the thymus nor in the
periphery of ODC-OVA mice at an amount that would be detect-
able by the high-affinity TCR of OT-I cells.
To extend our survey to the hematopoietic system, we also
repopulated WT mice with mixed bone marrow from OT-I and
ODC-OVA mice (1:4 ratio). The presence of the ODC-OVA trans-
gene in the bone marrow had no effect on the development of
OT-I cells in the same host (Figure 1E). Thus in ODC-OVA
mice, hematopoietic cells are also not responsible for the dele-
tion of OVA-reactive cells.
Perinatal Access to the CNS Allows Deletion
of Autoreactive CD8+ T Cells
Next, we considered perinatal access to ODCs in the CNS as an
opportunity for encounter with self-antigen leading to purging of
the repertoire. Previously, we had observed OT-I ODC interac-
tions in the brain of postnatal OT-I ODC-OVA double transgenic
mice undergoing EAE (Na et al., 2008), demonstrating the occur-
rence of such interactions. When carboxy fluorescein diaceteate
succinimidyl ester (CFSE)-labeled OT-I T cells were transferred
into 10-day-old ODC-OVA mice, they were expanded on day 5
and then deleted from the cervical LN (Figure 2A) and spleen
(not shown) on day 12 after transfer, indicating that they had
contacted OVA-presenting cells. Indeed, OVA expression was
readily observed in the developing brain as early as day 3 of
life (Figure S1 available online). In contrast, OT-I T cells trans-
ferred into adult ODC-OVA mice were neither expanded norImmunity 37, 134–146, July 27, 2012 ª2012 Elsevier Inc. 135
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Figure 1. Defective OVA-Specific CD8+ T Cell Response in ODC-OVA Mice
(A) OVA-reactive T cells after Lm-OVA infection. WT or ODC-OVA tg mice were infected with 5,000 cfu Lm-OVA, challenged 3 weeks later with 105 cfu, and
analyzed on day 6. OVA-Kb CD8+ T cells were determined by streptamer staining.
(B) Lack of OVA-Kb-specific CD8+ T cell precursors in LN cells from ODC-OVA mice. 2 3 108 total LN cells from WT or ODC-OVA mice were transferred into
Rag1/ mice. Spleens from recipient mice were analyzed 10 days after infection with 105 cfu Lm-OVA.
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Deletion of ODC-Reactive CD8+ T Cellsdeleted (Figure 2B). These data indicate that before the blood
brain barrier (BBB) closes, naive CD8+ T cells are able to contact
antigen-expressing ODCs in the CNS, leading to their activation
and deletion. Once the BBB is established, however, naive CD8+
T cells have no access to the CNS and hence remain ignorant of
the autoantigen OVA.
Our finding that transfer of OT-I T cells into young ODC-OVA
mice leads to their deletion rather than disease induction is
seemingly at odds with the aggressive EAE observed in OT-I
ODC-OVA double transgenic animals. Accordingly, we attemp-
ted to approach this extreme situation by increasing the number
of transferred OT-I cells per 7-day-old mouse from the 107 pres-
ently used to 5 3 107. Surprisingly, after 18 days, only 1 in 8
recipient ODC-OVAmice developed EAE whereas the remaining
mice remained healthy and effectively deleted the transferred
cells (Figures S2A and S2B). Histologic analyses revealed exten-
sive myelin damage in the diseased mouse whereas mice that
had successfully removed the autoreactive CD8+ T cells showed
normal brain architecture (Figure S2C). Thus, overwhelming
numbers of CD8+ T cells (at least 53 107) specific for a cytosolic
ODC antigen are required to cause serious damage even in
a youngmouse; below that threshold, they are deleted after initial
clonal expansion.
Peripheral Activation of ODC-Reactive CD8+ T Cells
Provides Antigen Access in Adult Mice, Leading
to Their Inactivation and Deletion
T cells specific for myelin antigens form part of the normal reper-
toire in rodents and humans (Martin et al., 1990; Ota et al., 1990;
Pette et al., 1990; Schluesener andWekerle, 1985). This situation
is modeled by the persistence of transferred naive OT-I cells in
the periphery of adult ODC-OVA mice. To investigate whether
opening of the BBB by immunization under inflammatory condi-
tions would provide access to the CNS and cause disease, we
infected adult ODC-OVA and WT mice, which had received 107
OT-I cells 1 day earlier, with Lm-OVA. In both the spleen (not
shown) and cervical LN (Figure 2C) of WT and ODC-OVA recip-
ient mice, robust clonal expansion was observed on day 5
postinfection (p.i.). However, in ODC-OVA mice, this expanded
population of OT-I cells showed impaired in vitro proliferation
and IFN-g secretion in response to the cognate peptide as
compared to the OT-I cells reisolated from WT recipients (Fig-
ure S3). Furthermore, although the expanded population of
OT-I cells persisted on day 10 p.i. in WTmice, it had been almost
fully eliminated in mice expressing OVA in the CNS (Figures 2C
and 3A). The disappearance of OT-I cells from the periphery
was not due their sequestration as viable cells in the CNS (which
did not exceed 1% of the inocula) (Figure S4), suggesting their
clonal deletion as a result of antigen encounter.Diagrams (A and B, right) show percentages of OVA-specific T cells of CD8+ T c
(C) Presence of Kb-SIINFEKL-reactive CD8+ T cells in LN from Vb5 or ODC-OVA
(D) Absence of high-avidity Kb-SIINFEKL-reactive CD8+ T cells in ODC-OVA Vb
concentrations of SIINFEKL peptide and the response was measured by intrace
(E) No deletion of developing OT-I cells by radioresistant thymic or hematopoeitic c
mixed bone marrow cells from OT-I Thy1.1 mice together with WT or ODC-OVA m
(F) CD8+ T cells were prepared from LN of recipient mice and cultured for 3 days
IFN-g secretion was detected by ELISA.
Data are representative of three independent experiments. See also Figure S5.In order to extend this observation to OVA-reactive CD8+
T cells from a normal repertoire, WT LN cells were transferred
into Rag-deficient mice with or without the ODC-OVA transgene
and were then infected with Lm-OVA. As shown in Figure 2D, the
robust SIINFEKL-Kb-specific CD8+ T cell response seen in non-
transgenic recipients was abolished by the ODC-OVA trans-
gene, indicating purging of the normal OVA-specific repertoire
during the response to Lm-OVA.
T cells may be enabled to cross the BBB either after specific
activation or as a result of local or systemic inflammation.
Because Lm-OVA infection leads to both systemic inflammation
and specific activation of OVA-reactive CD8+ T cells, we tried to
separate these factors by infecting adult mice with a CFSE-
labeled inocula of OT-I cells with either Lm or Lm-OVA. As
expected, infection with Lm-OVA, but not with Lm, led to
pronounced clonal expansion of OT-I cells in WT mice (Fig-
ure 3A). In ODC-OVA recipients, however, Lm infection sufficed
to induce cell division followed by deletion (Figure 3A). Thus,
inflammation-induced access to antigen resulted in proliferation
of antigen-specific peripheral naive CD8+ T cells, followed by
their removal from the immune system.
To evaluate the effects of CD8+ T cell activation itself on the
ability to reach the target antigen in the CNS, OT-I cells were
activated in vitro before transfer into adult recipients, and their
presence in cervical LN was monitored. In ODC-OVA mice, the
transferred activated OT-I cells were deleted, whereas they
declined only moderately in WT recipients, as is expected during
clonal contraction (Figure 3B). Note that as compared to the
deletion of naive peripheral CD8+ T cells stimulated by Lm-
OVA (Figure 2C), deletion occurred faster, presumably because
the phase of clonal expansion and sensitization to deletion had
occurred already in vitro. These data suggest that activated
CD8+ T cells can cross the BBB and interact with antigens ex-
pressed by ODCs, leading to their removal from the peripheral
repertoire.
Transplantation of OVA-Transgenic ODCs
into the Cerebellum Suffices for Deletion
of Peripheral OVA-Specific CD8+ T Cells
To rigorously rule out a contribution of OVA expressed outside of
the CNS to the observed deletion, in vitro cultured WT or ODC-
OVA ODC precursors were stereotactically transplanted into
the cerebellum of WT mice (Habisch et al., 2007). Three weeks
later, OVA expression was readily detectable in the cerebellum
of mice that had received transgenic, but not of those which
had received WT, cells (Figure 4A). OT-I CD8+ T cells were
then transferred followed by Lm-OVA infection. In the periphery
of mice transplanted with ODC-OVA ODCs, OT-I cells were
strongly reduced compared to recipient mice with a WT ODCells. Aggregate data from two independent experiments are shown.
Vb5 mice as shown by streptamer staining.
5 mice. Polyclonally preactivated CD8+ T cells were restimulated with titrated
llular (i.c.) detection of IFN-g.
ells of ODC-OVAmice. As indicated, irradiatedWT or ODC-OVAmice received
ice (1:4). 6 weeks later, spleen cells were stained for reconstitution of T cells.
with SIINFEKL. Proliferation was measured by 3H thymidine incorporation and
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Figure 2. Access of OT-I Cells to OVA-Expressing ODCs Leads to Their Activation and Deletion
(A) Activation and deletion of postnatally transferred OT-I cells in ODC-OVA hosts. CFSE-labeled OT-I Thy1.1 CD8+ T cells were transferred into 10-day-oldWT or
ODC-OVA mice; cervical LNs were analyzed 5 and 12 days later. See also Figures S1 and S2.
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Figure 3. Both Systemic Inflammation and Cell-Intrinsic Activation Lead to Deletion of OT-I Cells in Adult ODC-OVA Mice
(A) Deletion by systemic inflammation. Adult WT or ODC-OVAmice adoptively transferred with CFSE-labeled OT-I Thy1.1 CD8+ T cells were infected withWT Lm
or Lm-OVA; cervical LNs were analyzed 5 or 10 days after infection. Data are shown from two experiments with three to six animals, each with SD. See also
Figure S4.
(B) Deletion of transferred in vitro activated OT-I cells. In vitro activated OT-I CD8+ T cells were transferred into adult WT or ODC-OVAmice and cervical LNs were
analyzed at indicated time points. A CD8+ T cell gate was used in dot plots and graphs. Bar graph shows aggregate data from three experiments with two to three
animals each with SD.
See also Figure S5.
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Deletion of ODC-Reactive CD8+ T Cellstransplant (Figures 4B and 4C). These data show that the pres-
ence of OVA in CNS-resident ODCs is sufficient for deletion of
peripheral OVA-specific T cells after immune activation.
Deletion of ODC-Reactive CD8+ T Cells Is Blocked
by VLA-4-Specific mAb
If OVA expression in the CNS suffices for deletion of peripherally
activated OVA-reactive CD8+ T cells, these cells must migrate
into the CNS via the BBB. Interaction of very late antigen-4
(VLA-4) with its ligand, vascular cell adhesion molecule-1
(VCAM-1), which is expressed on CNS endothelium, is required
for T cell entry into the CNS (Yednock et al., 1992). Previous
reports had shown that VLA-4 Ab treatment reverses clinical
symptoms of EAE and results in the clearance of leukocytes
from the CNS (Kent et al., 1995; Le´ger et al., 1997). We therefore
transferred activated OT-I T cells into ODC-OVA mice under-(B) Antigenic ignorance of OT-I cells in adult ODC-OVA hosts. Naive OT-I CD8+ T
Cervical LNs were analyzed at indicated time points. Bar graph shows average p
(C) Activation and deletion of formerly ignorant OT-I cells in adult ODC-OVAmice a
T cells followed by infection with Lm-OVA; cervical LNs were analyzed at indicat
(D) Deletion of OVA-reactive CD8+ T cells from the normal repertoire by transg
transferred into Rag1/ or ODC-OVA Rag1/ mice. Spleens from recipient mic
Data shown in diagrams (right panels) were obtained with a CD8+ T cell gate and
experiments. See also Figure S5.going treatment with VLA-4-specific Ab. VLA-4 Ab-treated
ODC-OVA mice showed markedly reduced deletion of OT-I
T cells compared to isotype control Ab-treated mice, in line
with the notion that transgression of the BBB is required for the
deletion of OVA-reactive CD8+ T cells (Figure 5A).
Deletion of Autoreactive CD8+ T Cells Is Probably due
to Autoantigen Recognition on the ODCs Themselves
Recognition of OVA by OT-I cells could occur either directly on
ODCs, which express low amounts of Kb-SIINFEKL complexes
(about 90 per cell) (Na et al., 2009), or after antigen transfer to mi-
croglia or dendritic cells. First, we excluded expression of even
small amounts of cell-intrinsic OVA by microglia and dendritic
cells in ODC-OVA mice by using a sensitive polymerase chain
reaction (PCR) and flow cytometry-sorted cells (Figure S5). We
then tested for secondary presentation through the in vivocells were labeled with CFSE and transferred into adult WT or ODC-OVA mice.
ercent cell of OT-I among CD8+ T cells from five to seven mice.
fter Lm-OVA infection. ODC-OVA orWTmice received naive OT-I Thy1.1 CD8+
ed time points after infection. See also Figures S3 and S4.
enic expression of OVA in ODCs. 2 3 108 total LN cells from WT mice were
e were analyzed 10 days after infection with 105 cfu Lm-OVA.
are presented as mean ± standard deviation (SD) of two to three independent
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Figure 4. Transplantation of ODCs from ODC-OVA Mice Confers Deletion of OT-I Cells in Lm-OVA-Infected WT Mice
(A) Detection of OVA in transplanted ODCs. Cultured ODC precursors from WT or ODC-OVA mice were transplanted into the cerebellum of WT recipient mice
3 weeks before analysis by immune histology. OVA staining was seen throughout the whole cerebellar white matter only in mice transplanted with OVA-ODC.
(B and C) Deletion of OT-I cells. 3 weeks posttransplantation, mice received CFSE-labeled OT-I CD8+ T cells i.p. followed by Lm-OVA infection; OT-I cells
recovered from cervical LN were analyzed on days 5 and 10 p.i. A CD8+ T cell gate was used in dot plots and graphs. Aggregate data from two independent
experiments are shown.
See also Figure S5.
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Deletion of ODC-Reactive CD8+ T Cellsactivation of TCR transgenic CD4+ T cells (OT-II cells). Previ-
ously, we had shown that if OVA is released from ODCs by an
overwhelming number of CD8+ T cells, as is the case in OT-I
ODC-OVA double transgenic mice, activation of OT-II cells is
readily observed in the cervical LN (Na et al., 2008). Accordingly,
in vitro activated CFSE-labeled OT-I CD8+ T cells were trans-
ferred to adult ODC-OVAmice together with naive CFSE-labeled
OT-II cells as indicators for secondary presentation. As
expected, transferred OT-I T cells were deleted in ODC-OVA
but not in WT recipients, whereas the cotransferred OT-II cells
remained quiescent in both WT and ODC-OVA mice (Figure 5B).
Thus at least with regard to DCs, which also present antigens via
the MHC class II endocytic pathway, secondary presentation of
cytosolic OVA derived fromODCs does not seem to play a role in
antigen recognition by and deletion of OT-I cells.
As a second test for the direct recognition of Kb-SIINFEKL on
ODCs by OT-I cells, we used blockade with mAb 25D1.16, which
selectively binds to this MHC-peptide complex (Porgador et al.,140 Immunity 37, 134–146, July 27, 2012 ª2012 Elsevier Inc.1997). In vivo, 25D1.16 is able to block activation of OT-I cells by
OVA-transgenic ODCs, but not by exogenous OVA cross-pre-
sented by dendritic cells (Na et al., 2009). When in vitro preacti-
vatedOT-I cells were transferred into ODC-OVAmice, which had
also received 25D1.16, deletion was fully prevented (Figure 5A).
This result supports our hypothesis that deletion of OVA-reactive
CD8+ T cells is a consequence of antigen recognition at the
surface of ODCs as opposed to cross-presentation by profes-
sional APCs.
Deletion of Autoreactive CD8+ T Cells by Autoantigen-
Expressing ODCs Involves Fas-Mediated Apoptosis
OVA recognition by OT-I cells on ODCs results in IFN-g
release in vivo (Na et al., 2008). Because IFN-g induces
FasL expression in ODCs (Pouly et al., 2000), triggering of
apoptosis in antigen-activated CD8+ T cells by the Fas pathway
appeared as a possible mechanism for the observed deletion.
To test this, we blocked FasL with a Fas-Fc fusion protein in
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Figure 5. Deletion of OT-I Cells in ODC-OVA Mice Requires Migration and OVA Recognition on ODCs
(A) Blockade with antibodies. In vitro activated CFSE-labeled OT-I Thy1.1 cells were transferred into WT or ODC-OVA mice that received Abs to VLA-4 or to the
Kb-SIINFEKL complex on days 1, +2, and +4 of cell transfer. On day 5, cervical LNs were analyzed with a CD8+ T cell gate.
(B) Absence of OVA crosspresentation to OT-II cells in OT-I deleting ODC-OVAmice. Naive CFSE-labeled OT-II CD4+ T cells were transferred intoODC-OVAmice
together with in vitro activated CFSE-labeled OT-I Thy1.1 CD8+ T cells; 5 days later cervical lymphocytes were stained for FACS analysis. The data are
representative of three independent experiments.
See also Figure S5.
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Deletion of ODC-Reactive CD8+ T CellsLm-OVA-infected ODC-OVA mice and indeed observed
substantial if not complete prevention of OT-I T cell deletion
(Figure 6A).
Taken together, our data suggest that antigen recognition on
ODCs by previously activated CD8+ T cells scanning the brain
induces their apoptosis in situ. As in other settings where high
numbers of lymphocytes undergo apoptosis, such as thymic
T cell selection, it was, however, difficult to ‘‘find the bodies’’
by immune histology or flow cytometry because of their very
rapid removal by macrophages. We therefore devised a method
that exploits transfer of the lipophilic dye CM-Dil to the phago-
cytes that eat the labeled cells. Indeed, a pilot experiment
employing apoptosis induction in labeled thymocytes in the
presence of peritoneal macrophages showed strong transfer of
label from the thymocytes to the phagocytes (Figure 6B).
This method was then used to look for traces of dead OT-I
cells in the CNS. Indeed, flow cytometry revealed a significant
number of labeled microglia cells in ODC-OVA, but only a few
in WT mice that had received labeled OT-I cells 3 days earlier
(Figure 6C). Labeled microglia cells were also visible by immune
histology of the cerebellum (Figure 6D). Taken together, our data
indicate that removal of apoptotic ODC-reactive CD8+ T cells
occurs at least in part within the CNS itself.
CNS Infection Makes ODCs Susceptible to CD8+ T Cell
Attack
The ability of ODCs to delete even a large number of CD8+ T cells
from the repertoire begs the question how the immune systemcan successfully deal with intracellular pathogens infecting the
brain. To address this issue, the site of infection with Lm-OVA
was moved from the periphery to the CNS. Based on previous
experience with mice expressing OVA in neurons (Sanchez-
Ruiz et al., 2008), ODC-OVA and control mice received only
106 OT-I cells 1 day prior to an intracerebral infection with 103
Lm-OVA. Interestingly, starting at day 8 after infection, after
complete elimination of the bacteria from the CNS, 100% of
ODC-OVA mice developed limp tail weakness and hind leg
paresis that persisted throughout the entire period of the study,
i.e., 50 days after infection, whereas all WT mice (Figures 7A and
7B) and infected ODC-OVA mice without OT-I transfer (not
shown) remained healthy. Neuropathological analysis identified
a CD8+ T cell-mediated autoimmune response directed against
ODCs in brain and spinal cord. One day preceding neurologic
symptoms, numerous CD8+ T cells had homed to the brain of
ODC-OVA mice, preferentially to the white matter where they
formed inflammatory clusters (Figure 7C). In the spinal cord,
CD3+ T cells were present in the posterior column (Figure 7E).
Inflammation progressed up to day 14 after infection, when de-
myelination in the brain and the spinal cord was prominent (Fig-
ure 7G). In contrast, only a few CD3+ T cells patrolled the CNS in
WT mice, and demyelination was absent (Figures 7F and 7H).
DISCUSSION
We have reported here the efficient deletion of autoreactive
CD8+ T cells from the immune system by ODCs expressing theirImmunity 37, 134–146, July 27, 2012 ª2012 Elsevier Inc. 141
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Figure 6. Deletion of OT-I T Cells in ODC-OVA Mice Involves Fas-Mediated Apoptosis
(A) Inhibition of deletion by blockade of FasL. ODC-OVA or WT mice were treated with 1 mg of Fas-Fc fusion protein every second day, starting 1 day before
adoptive transfer of OT-I CD8+ T cells. Next day, mice were infected with Lm-OVA; cervical LNs were analyzed on day 10 p.i. with a CD8+ T cell gate.
(B) Use of lipophilic dye to detect macrophages having digested apoptotic cells. CM-Dil-labeled thymocytes were cultured overnight with peritoneal macro-
phages in the presence of dexamethason and analyzed by flow cytometry.
(C) Microglia cells dispose of apoptotic OT-I cells in ODC-OVA mice. In vitro activated CM-Dil-labeled OT-I cells were transferred into WT or ODC-OVA mice.
3 days later, leukocytes were prepared from brain and spinal cord and analyzed by flow cytometry for CM-Dil-labeled Mac1+ cells.
(D) Detection of CM-Dil-labeled microglia cells in situ. Cryosections were stained for Mac-3 expression (green). Note scattered CM-Dil-labeled microglia cells in
cerebellum of ODC-OVA mice 3 days after transfer of in vitro preactivated CM-Dil-labeled OT-I cells. Scale bars represent 20 mm. Aggregate data from two
independent experiments are shown.
See also Figure S5.
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Deletion of ODC-Reactive CD8+ T Cellscognate antigen in the uninfected brain, whereas demyelinating
CD8+ T cell-mediated disease ensues if the CNS itself is infected
with an intracellular pathogen expressing the sameODC autoan-
tigen. Deletion requires recirculation through the CNS and
can occur either postnatally, when the BBB is not fully formed
yet, or in the adult if CD8+ T cells are enabled to enter the
CNS. Enablement can be cell intrinsic, i.e., a result of their
activation, or due to systemic inflammation. Both neonatal and
adult purging of ODC-reactive CD8+ T cells is preceded by
a proliferative phase that is likely to be required for sensitizing
the cells to activation-induced cell death (Plunkett et al., 2000)
and during which the functional fitness of autoreactive CD8+
T cells headed for deletion is already impaired. Deletion of
ODC-reactive CD8+ T cells in the perinatal period is seen both
in mice with an unmanipulated repertoire and ‘‘Vb5 mice’’ with
a CD8+ T cell repertoire enriched for OVA reactivity, the model
antigen employed, and after transfer of high numbers (up to142 Immunity 37, 134–146, July 27, 2012 ª2012 Elsevier Inc.5 3 107) of high-affinity OVA-reactive OT-I cells into 7-day-old
ODC-OVA mice. Thus, ODCs readily cope with even an unphy-
siologically high representation of autoreactive CD8+ T cells
during the perinatal period.
Initially, we had suspected that perinatal deletion of Kb-
SIINFEKL-reactive cells in ODC-OVA mice is due to intrathymic
antigen expression. Medullary epithelial cells are potent negative
selectors of the emerging T cell repertoire by ectopic expression
of tissue antigens or fragments thereof (Kyewski and Klein,
2006). This has also been reported for MBP (Farhadi et al.,
2003), the protein lending ODC specificity to OVA in ODC-OVA
mice via its regulatory sequences, and for OVA itself expressed
under the control of the rat insulin promotor (Kurts et al., 1996,
1997b). Our earlier search for thymic OVA by immune histology,
immunoblotting, or RT-PCR had failed to provide such evidence
in ODC-OVA mice (Cao et al., 2006), and in our current
experiments, negative selection by thymic or extrathymic
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Figure 7. Intracerebral Infection of OT-I-Loaded ODC-OVA Mice Leads to Demyelinating Disease
(A and B) EAE score and incidence. ODC-OVA and WT mice received an i.v. injection of 106 OT-I CD8+ T cells 1 day prior to intracerebral infection with 103 Lm-
OVA and were monitored for EAE score. Mean and SD are shown (Mann-Whitney U test; *p < 0.05; **p < 0.025).
(C–H) Neuropathological characteristics.
(C and D) CD8+ T cell infiltration in periventricular white matter 7 days p.i. in ODC-OVA (C) but not WT (D) mouse.
(E and F) Numerous CD3+ T cells in the posterior column of the spinal cord in an ODC-OVA mouse at day 7 after infection (arrows, E), whereas only single CD3+
T cells reside at the border of the graymatter to the whitematter of the posterior column of the spinal cord in a C57BL/6mouse (arrows, F). Immunohistochemistry
with slight hemalum counterstaining, original magnification 3200.
(G and H) Widespread demyelination in the spinothalamic fascicle at day 14 after infection (arrows, G). Insert in (G) demonstrates vacuolar demyelination and
myelin debris in the spinothalamic fascicle. Spinal cord of WT control mouse is normal (H).
See also Figure S5.
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Deletion of ODC-Reactive CD8+ T Cellsradioresistant or hematopoietic cells was ruled out by using adult
bone marrow radiation chimeras.
Perinatal tolerance induction by a tissue-specific self antigen
has previously been reported for CD8+ T cells recognizing trans-genic Kb on keratinocytes (Alferink et al., 1998). Similar to our
findings, access to antigen through trafficking in the neonate
was required for tolerance induction, but the outcome was func-
tional rather than deletional tolerance.Immunity 37, 134–146, July 27, 2012 ª2012 Elsevier Inc. 143
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Deletion of ODC-Reactive CD8+ T CellsIn spite of the remarkable efficiency of perinatal deletion
currently observed, myelin-specific CD8+ T cells are found in
the periphery of both humans and rodents (Martin et al., 1990;
Ota et al., 1990; Pette et al., 1990; Schluesener and Wekerle,
1985), presumably because of export from the thymus after
formation of the BBB. By using adult ODC-OVA mice adoptively
transferred with OT-I cells, we found that such cells can indeed
persist in the immune system. However, provision of access to
the CNS by systemic inflammation or by activation of the autor-
eactive CD8+ T cells themselves was sufficient to induce deletion
also in the adult setting. Accordingly, removal of autoreactive
CD8+ T cells from the repertoire by recirculation through the
CNS appears to be a life-long series of events triggered by
infections.
Several independent experimental approaches strongly
suggest that deletion of the recirculating CD8+ T cells is due to
autoantigen expression by the ODCs themselves: PCR analysis
showed its exclusive expression in ODCs and stereotactic trans-
plantation mapped the effect to this cell type. In addition, inter-
ference of VLA-4 blockade with deletion provides further support
for the need for CD8+ T cells to cross the BBB (Yednock et al.,
1992). A requirement for crosspresentation by professional
APC appears unlikely for the following reasons. First, we have
previously shown by using mixed ODC cultures from wild-type
and ODC-OVA mice expressing H-2b or H-2d that H-2b ODC-
OVA ODCs and not contaminating cross-presenting cell types
directly activate OT-I cells (Na et al., 2008). Second, the failure
to see activation of OT-II CD4+ T cells cotransferred with OT-I
T cells into ODC-OVA mice at least rules out the participation
of DCs which re-present antigens to both CD4+ and CD8+
T cells. Finally, we have previously shown that recognition of
exogenously applied OVA by OT-I cells cannot be blocked by
the Kb-SIINFEKL-specific mAb 25D1.16 in vivo, whereas OT-I
activation by OVA-expressing ODCs is readily blocked both
in vitro and in vivo (Na et al., 2009). The ability of this mAb to fully
interfere with OT-I deletion, therefore, strongly suggests that
recognition leading to deletion occurred on the oligodrendocytes
themselves, rather than by cross-presenting professional APCs.
This is in contrast to the deletion of autoreactive OT-I CD8+
T cells in the rat insulin promoter (RIP)-mOVA model, which
depends on cross-presentation of pancreatic b cell-derived
OVA by resting dendritic cells in the draining LN and reaches
saturation of its protective capacity already at 106 transferred
cells (Kurts et al., 1997a).
Together, our data indicate that antigen recognition on ODCs
by CD8+ T cells scanning the brain leads to their destruction. The
observed participation of the Fas-FasL system in apoptotic
removal of CD8+ T cells is in keeping with the known ability of
IFN-g produced by the attacking CD8+ T cells (Na et al., 2008)
to upregulate FasL on ODCs (Pouly et al., 2000) but does not
rule out the participation of FasL expressed by other cells.
Together, our results suggest a scenario where ODC-specific
CD8+ T cells gain access to the CNS as a result of specific acti-
vation or peripherally induced inflammation. Here, they acquire
sensitivity to apoptosis induction by antigen recognition on
ODCs while downregulating their effector functions. After further
recirculation, through the periphery and the CNS, they finally
receive a death signal from the ODCs that have upregulated
FasL. Only recently, a distinct time-window of recirculation of144 Immunity 37, 134–146, July 27, 2012 ª2012 Elsevier Inc.OVA-specific CD8+ T cells through the CNS has been described
after Lm-OVA infection, in line with our proposal (Young et al.,
2011).
Another nonlymphoid extrathymic cell type was recently
reported to delete autoreactive CD8+ T cells (Lee et al., 2007).
These specialized LN stromal cells use the autoimmune regu-
lator Aire to promiscuously express tissue-specific antigens to
CD4+ and CD8+ T cells, much like thymic medullary epithelial
cells. In contrast, ODCs do not express MHC class II glycopro-
teins (Turnley et al., 1991) and only low amounts of MHC
class I, which are increased by IFN-g exposure.
Death of CD4+ T lymphocytes in the brain of mice undergoing
EAE has been extensively described (Gold et al., 2006; Pender
et al., 1991; Schmied et al., 1993). However, although these
reports document T cell apoptosis in situ (Schmied et al.,
1993), they do not describe purging of the peripheral immune
system by filtration through the CNS. Myelin-reactive CD8+
T cells may behave differently from CD4+ T cells, because they
can find their target antigen onODCs themselves, not depending
on their representation by microglia or DCs.
Importantly, we found one setting in which the ability of ODCs
to purge the peripheral repertoire is turned into the opposite: if
infection is in the CNS itself, the invading CD8+ T cells are
enabled to destroy ODCs expressing a pathogen-derived (and
maybe also a crossreactive self-) antigen. Thus, presence or
absence of local inflammation in the CNS decides whether
CD8+ T cells will destroy ODCs on which they detect an antigen,
or will be destroyed themselves. Although this important deci-
sion-making process is clear from our present work, future
research will clarify its precise cellular and molecular mecha-
nisms. Whatever these may be, our studies may open the door
for a better understanding of the role of antiviral CD8+ T cell
responses, in particular to EBV (Jilek et al., 2008), in the develop-
ment of MS. Indeed, the reported crossreactivity of EBV-specific
CD8+ T cells with myelin antigens (Lang et al., 2002) and the
presence of EBV in B cells of the CNS of MS patients (Serafini
et al., 2007; Stowe et al., 2007) may provide a setting where local
inflammation prevents ODCs from removing potentially harmful
CD8+ T cells.
EXPERIMENTAL PROCEDURES
Mice
ODC-OVA mice (Cao et al., 2006), OT-I TCR transgenic mice (Hogquist et al.,
1993), Vb5 TCRb chain transgenicmice (Fink et al., 1992), and Thy1.1 congenic
C57BL/6 mice (Jackson ImmunoResearch Laboratories) were kept in path-
ogen-free animal facilities. All in vivo studies were performed according to
NIH guidelines under permits from the governments of Lower Frankonia (for
Wu¨rzburg) and North-Rhine Westphalia (Cologne).
L. monocytogenes Infection
Mice were infected with 105 colony forming units (cfu) Lm-OVA (Pope et al.,
2001) or WT Lm in PBS intravenously. To prime for secondary responses,
mice were infected with 5,000 cfu 3 weeks earlier. Intracerebral infection of
mice was performed and disease severity was scored on a 1 to 6 scale as
described previously (Sanchez-Ruiz et al., 2008).
CD8+ T Cell Isolation and In Vitro Activation
CD8+ T cells were isolated from the LN of OT-I mice via MACS beads (Miltenyi
Biotech, Bergisch-Gladbach, Germany) and labeled with 10 mMCFSE (Invitro-
gen, Grand Island, NY). For stimulation, isolated CD8+ T cells were cultured
Immunity
Deletion of ODC-Reactive CD8+ T Cellswith anti-CD3- plus anti-CD28-coated beads (Invitrogen) in the presence of
recombinant human (rh) IL-2 (Novartis, Basel, CH) for 6 days and labeled
with 10 mM CFSE. Cells were transferred i.p. into WT or ODC-OVA mice.
Determination of functional avidity of SIINFEKL-specific CD8+ T cells
followed the protocol by Zehn and Bevan (2006).
Bone Marrow Chimeras
Irradiated (11.5Gy) mice received 1.6 3 107 bone marrow cells from WT or
ODC-OVA mice together with 4 3 106 bone marrow cells from OT-I Thy1.1
mice i.v. Analysis was 6 weeks later.
ODC Cultivation and Transplantation
ODC precursor cells were isolated and cultured as previously described
(Na et al., 2008). 5 3 104 cultured ODCs were stereotactically implanted into
left and right areas of the cerebellum. Coordinates were as follows: P, 6.5;
L, ±1.7; V, 1.6 mm from bregma and dural surface with the toothbar set at 5,
earbar at 10; injection rate, 0.25 ml/min; cannula left in place for 2 min. Mice
were used for OT-I transfer experiments 3 weeks later.
In Vivo Application of Antibodies and FasL Blocking Fusion Protein
Mice were treated with 75 mg of VLA-4 Ab (Southern Biotechnology Inc.,
Cambridge, MA), 100 mg of isotype control, or 100 mg of 25D1.16 Abs
(Porgador et al., 1997) i.p. on days 1, +2, and +4 of cell transfer. For FasL
blocking, 1 mg Fas-Fc fusion protein (Apogenix, Heidelberg, Germany) was
injected i.p. every second day after Lm-OVA infection for 10 days.
Flow Cytometry
Lymphocytes were stained with the following Abs (all from BD PharMingen):
anti-CD8-FITC, anti-CD8-APC, anti-CD90.1-PerCP, and anti-TCR Va2-PE.
Streptamer staining was performed by Strep-Tactin kit (IBA, St. Louis, MO)
as described by the manufacturer. Data were acquired on a FACSCalibur (BD
Bioscience) and analyzed by FlowJo software (Tree Star Inc, Ashland, OR).
Histopathology
Brain and spinal cord were embedded in Paraffin or Tissue-Tek O.C.T.
compound (Sakura Finetek). Cresyl vivolet-luxol fast blue staining and immu-
nohistochemical staining was performed as described previously (Na et al.,
2008; Sanchez-Ruiz et al., 2008).
Leukocyte Isolation from Spinal Cord
Leukocytes were isolated from spinal cords with percoll gradient as described
previously (Na et al., 2008) and analyzed by flow cytometry.
Cell Labeling with CM-Dil
Thymocytes or LN cells were stained with 10 mMCM-Dil (Invitrogen) according
tomanufacturer’s instructions. Labeled thymocytes were cocultured with peri-
toneal macrophages overnight in the presence of 10 nM dexamethasone
(Sigma) and stained for flow cytometry analysis.
Statistical Analysis
Analysis was performed by GraphPad Prism 4.0 (GraphPad Software). Data
are presented as mean ± SD; p values were determined by two-tailed
Student’s t tests.
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